Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06815991Phase 1Recruiting

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

Role: lead

NCT05878119Phase 2Completed

Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program

Role: lead

NCT06882096Phase 1Recruiting

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

Role: lead

NCT05038488Phase 2Completed

Phase 2a MIB-626 vs. Placebo COVID-19

Role: lead

NCT04817111Phase 2Completed

NAD+ Precursor Supplementation in Friedreich's Ataxia

Role: lead

All 5 trials loaded